Fall school reopening plans demonstrate continued data gap

Vaccine options for children ages 12 and older (now Pfizer, soon Moderna) make in-person education a safe bet for a lot of families. But younger students will likely have to wait much longer for their shots. As a result, regular testing will continue to be a key safety strategy… but school testing data continue to be hard to come by.

Read More

Moderna for the middle children

Good news for kids hoping for jabs in arms: Moderna has announced promising results for its trial in adolescent-aged children. In around 4,000 adolescents, the vaccine proved to be 94.1% effective in preventing disease. No cases in the vaccinated group were found two weeks after the second shot, while 4 cases were found in the unvaccinated control group.

Read More

National numbers, May 30

Cases, deaths, and hospitalizations all continue to drop nationwide. The U.S. reported about 3,000 COVID-19 deaths last week, in total—at the peak of the winter surge, we saw more than 3,000 deaths a day.

Read More

The CDC needs to release state-by-state data on who’s getting vaccinated

This week, we finally got demographic state-by-state vaccination data from the CDC. Well… sort-of. A team from KHN received CDC state-by-state demographic vaccination data via a public records request. The data indicate that, despite promises from the White House to prioritize vulnerable communities in the vaccination campaign, a lot of inequities persist.

Read More